All three isoforms of PIM kinase are expressed in a panel of NSCLC cell lines.

- PIM kinase is expressed in ~90% of NSCLC tumour tissues across all stages of the disease.
- PIM kinase is a promising new therapeutic target for the treatment of NSCLC patients.

Dual PI3K/PIM kinase (IBL-202) targeted therapies have demonstrated pro-apoptotic and anti-proliferative activity in-vitro and in-vivo and should be considered in the treatment of NSCLC patients.